California patients purchasing cannabis from licensed retailers will gain enhanced access to product testing information under Assembly Bill 1965, signed into law on September 27, 2026. The legislation amends Sections 26070, 26100, and 26104 of the California Business and Professions Code, expanding the authority of the California Department of Cannabis Control (DCC) to oversee cannabis product testing and establishing new requirements for retailers to provide customers with laboratory testing documentation.
Starting January 1, 2027, licensed retailers and other businesses authorized for retail cannabis sales must provide the Certificate of Analysis (COA) upon customer request. A COA documents testing results for cannabinoid concentrations, including THC and CBD, as well as for residual pesticides, processing chemicals, heavy metals, microbial impurities, mycotoxins, and other regulated contaminants. According to the DCC's official cannabis testing guidance, licensed laboratories already examine these factors before products enter the legal market, and COAs identify whether a product batch meets applicable requirements.
The new law also authorizes the DCC to obtain or access cannabis products offered for retail sale for independent, off-the-shelf laboratory testing. It mandates performance testing to ensure consistency across facilities, including retesting and laboratory procedure improvements. These provisions build upon California's existing cannabis quality assurance framework, and the DCC's cannabis laws and regulations provide further information about the regulatory requirements governing licensed cannabis businesses.
AB 1965 does not change medical marijuana recommendation eligibility or introduce new requirements for obtaining a physician's recommendation. The state's Medical Marijuana Identification Card Program remains a separate, voluntary program administered through county health departments. According to the California Department of Public Health's official MMIC guidance, applicants seeking a county-issued medical marijuana identification card must provide documentation that includes a physician's medical recommendation, proof of identity, and proof of residency. Patients should understand the difference between medical cannabis recommendations, county-issued identification cards, and product testing regulations.
For patients preparing for the upcoming requirements, practical steps include learning how COAs document cannabinoid concentrations and contaminant testing, verifying retailer licensing before purchase, requesting product testing information once the new requirement takes effect, keeping medical documentation current, and monitoring official regulatory updates from the DCC and the California Department of Public Health. The law's transparency provisions are designed to strengthen product testing oversight and give consumers more information about the cannabis products they purchase. While a COA can help consumers review cannabinoid concentrations and testing results for substances such as pesticides, heavy metals, and microbial contaminants, it does not establish whether a particular cannabis product is medically appropriate for an individual patient. The changes should not be interpreted as modifications to individual medical eligibility or physician certification standards.
The announcement from Medical Marijuana Card California emphasizes that patients should verify current requirements through California government agencies and consult qualified healthcare or legal professionals when appropriate. The new law is expected to increase transparency in the licensed cannabis market and provide patients with greater access to laboratory information about potential products.
